Foundayo vs Wegovy
Oral GLP-1 Pill vs Weekly Injectable — Complete Comparison (2026)
Foundayo (orforglipron) is Eli Lilly's oral non-peptide GLP-1 pill — no injection, no fasting. Wegovy (semaglutide 2.4 mg) is Novo Nordisk's weekly injectable GLP-1, the FDA-approved gold standard for obesity. Compare them head-to-head to decide which fits your lifestyle.
Foundayo vs Wegovy: At a Glance
- ✓Non-peptide oral GLP-1 receptor agonist (small molecule)
- ✓Once-daily pill — no injection needed
- ✓No fasting or timing restrictions
- ✓Phase 3 ATTAIN-1: up to 27.3 lbs weight loss at 72 weeks
- ✓Phase 2: ~14.7% body weight loss at 36 weeks
- ✓Eli Lilly — FDA submission underway
- ✓Peptide-based GLP-1 receptor agonist
- ✓Once-weekly subcutaneous injection (autoinjector pen)
- ✓FDA-approved for obesity (BMI ≥30 or ≥27 + comorbidity)
- ✓STEP-1: 14.9% mean body weight loss at 68 weeks
- ✓SELECT trial: 20% cardiovascular risk reduction
- ✓Novo Nordisk — widely available since 2021
Detailed Comparison
| Feature | Foundayo (Orforglipron) | Wegovy (Semaglutide) |
|---|---|---|
| Brand Name | Foundayo | WegovyBest |
| Generic Name | Orforglipron (LY3502970) | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Drug Type | Non-peptide small molecule | Peptide biologic (GLP-1 analogue) |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Administration | Once-daily oral pill | Once-weekly subcutaneous injection |
| Fasting Required | No — take with or without food | N/A (injectable) |
| Dose Range | 3–45 mg daily (oral) | 0.25–2.4 mg weekly (SC injection) |
| Half-life | ~28–47 hours | ~7 days |
| Key Weight Loss Data | Phase 2: ~14.7% at 36 wks; ATTAIN-1: up to 27.3 lbs at 72 wks | STEP-1: 14.9% at 68 wks (2.4 mg) |
| CV Outcome Data | Not yet reported | SELECT: 20% MACE reduction |
| FDA Status | Regulatory submission underway (2026) | FDA-approved (June 2021) |
| Storage | Room temperature (no refrigeration) | Refrigerated until first use |
| Side Effects | Nausea, vomiting, diarrhea (dose-dependent) | Nausea (~44%), vomiting, diarrhea, constipation |
Weight Loss Comparison
Choose Based on Your Priorities
No Needles
Foundayo is a daily pill — ideal if you're needle-phobic or prefer oral medication. No injection site rotation, no sharps disposal.
Proven Track Record
Wegovy has been FDA-approved since 2021 with extensive real-world data, cardiovascular outcome data (SELECT), and established insurance coverage.
Convenience
Foundayo: daily pill, any time, with food. Wegovy: weekly injection but only once per week. Choose based on your preference for daily vs weekly.
Cardiovascular Benefits
Wegovy's SELECT trial showed 20% MACE reduction in obesity + CVD. Foundayo does not yet have cardiovascular outcome data.
Storage & Travel
Foundayo stores at room temperature — easy for travel. Wegovy requires refrigeration until first use and has cold chain logistics.
Cost & Access
Wegovy is widely available but expensive (~$1,300-1,400/mo uninsured). Foundayo may be more affordable as a small molecule, but pricing TBD.
Which Should You Choose?
Foundayo (orforglipron) and Wegovy (semaglutide) are both GLP-1 receptor agonists, but they represent fundamentally different approaches to weight loss medication. Foundayo is a non-peptide oral pill taken daily without restrictions. Wegovy is a peptide-based weekly injection with FDA approval and extensive clinical evidence.
If you prioritize convenience and hate needles, Foundayo offers a major lifestyle advantage — a pill you take with breakfast (or any time). If you prioritize proven long-term data, cardiovascular risk reduction, and insurance coverage, Wegovy has a multi-year head start with the FDA approval and SELECT cardiovascular trial data.
For many patients, the choice may come down to timing. Wegovy is available now. Foundayo is pending FDA approval. If you're starting GLP-1 therapy today, Wegovy is the established option. If you can wait, Foundayo's oral convenience could be worth it.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Important Context for This Comparison
This comparison uses data from separate clinical trials (ATTAIN for Foundayo, STEP for Wegovy). Cross-trial comparisons are informative but imperfect — differences in patient populations, trial design, follow-up duration, and endpoint definitions mean numbers from separate trials are not directly interchangeable.
A direct head-to-head trial between Foundayo and Wegovy would provide the most definitive comparison. Until such data is available, this comparison provides useful context based on the best available evidence from each drug's respective trials.
Tracking your personal response data in Shotlee is particularly valuable when considering a switch. By documenting your outcomes on your current protocol — efficacy, side effects, adherence, and quality of life — you create an objective baseline for comparison if you transition to the alternative.
Foundayo vs Wegovy: Frequently Asked Questions
Neither is universally better. Foundayo offers oral convenience (daily pill, no fasting). Wegovy has FDA approval, proven cardiovascular benefits, and years of real-world data. Your choice depends on needle tolerance, insurance coverage, and personal preference.
Phase 2 data shows ~14.7% weight loss for Foundayo at 36 weeks, comparable to Wegovy's 14.9% at 68 weeks in STEP-1. Phase 3 ATTAIN-1 shows up to 27.3 lbs loss. Direct head-to-head trials would be needed for definitive comparison.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols including timing and starting dose. Track both in Shotlee for comparison data.
No. Foundayo is an oral pill taken once daily. Wegovy is a subcutaneous injection given once weekly. This is the key differentiator for many patients.
Yes. Shotlee supports tracking any GLP-1 medication including Foundayo, Wegovy, Ozempic, Mounjaro, and more. You can compare your results across different protocols.
Track Foundayo or Wegovy in Shotlee
Free dose tracking, side effect logging, weight trends, and outcome comparison for any GLP-1 protocol.
📚References & sources
Latest on Foundayo
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read